Understanding : Vitiligo A Skin Conditions Beyond Color

Year : 2026 | Volume : 16 | 01 | Page :
    By

    Bharati.S.Chavan,

  • Sunila.A.Patil,

  • Sunil.P.Pawar,

  1. Student, B. Pharm, Department of Pharmaceutics, P. S. G. V. P. Mandal’s College of Pharmacy,Shahada, Maharashtra, India
  2. Associate Professor, Department of Pharmaceutical Chemistry, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
  3. Principal, Department of Pharmaceutical Chemistry, P. S. G. V. P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India

Abstract

Patches of skin that have lost their pigmentation are the hallmark of vitiligo, a chronic skin disorder. The afflicted skin patches turn white and typically have strong edges. Additionally, the skin’s hair may turn white. There may also be issues with the inside of the mouth and nose. The rate at which skin conditions cause color loss is uncertain. When the cells that make melanin cease to function or die, vitiligo results. People of all skin types can get vitiligo, but those with darker complexion may notice it more. A family history of the illness or other autoimmune illnesses is one risk factor. This poll focuses on how natural products made from plants can aid with vitiligo.Findings 449 men and 496 women (m:f 1:1.1) with vitiligo ranging from 1 week to 64 years (mean 5.1 years) and ages 2 to 83 years (mean 24.4 years) were included. Of the patients, 248 (26.2%) were children aged ≤12 years, and 478 (50.6%) were adults aged ≤20 years. The majority of 674 (71.3%) individuals experienced it before the age of 25, and the age at onset ranged from 6 months to 82 years (mean 20.5 years).

Keywords: Herbs, herbal medicine, remedies, treatments, vitiligo, melanocytes, repigmentation

How to cite this article:
Bharati.S.Chavan, Sunila.A.Patil, Sunil.P.Pawar. Understanding : Vitiligo A Skin Conditions Beyond Color. Research and Reviews: A Journal of Pharmacology. 2025; 16(01):-.
How to cite this URL:
Bharati.S.Chavan, Sunila.A.Patil, Sunil.P.Pawar. Understanding : Vitiligo A Skin Conditions Beyond Color. Research and Reviews: A Journal of Pharmacology. 2025; 16(01):-. Available from: https://journals.stmjournals.com/rrjop/article=2025/view=233271


References

1. Zedan H, Abdel-Motaleb AA, Kassem NM, et al. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg 2015; 19:144.
2. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386:74.
3. Mohammed GF, Gomaa AH, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases 2015; 3:221.
4. Ortonne J-P, Passeron T. Vitiligo and other disorders of hypopigmentation. In: Dermatology,3rd ed, Boloniga JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, 2012. p.1023.
5. Krüger C, Schallreuter KU. Stigmatisation, Avoidance Behaviour and Difficulties in Copingare Common Among Adult Patients with Vitiligo. Acta Derm Venereol 2015; 95:553.
6. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with
vitiligo. Pediatr Dermatol 2014; 31:309.
7. Robins A. Biological Perspectives on Human Pigmentation, Cambridge University Press, 2005. Vol 7.
8. Grimes PE. Disorders of pigmentation. In: ACP Medicine, Dale DC, Federman DD (Eds), Web MD Scientific American Medicine, 2012. P.526.
9. Porter J. The psychological effects of vitiligo: Response to impaired appearance. In: Vitiligo,Hann SK, Nordlund JJ (Eds), Blackwell Science, 2000. P.97.
10. Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol 2015; 56:85.
11. Abu Tahir M, Pramod K, Ansari SH, Ali J. Current remedies for vitiligo.Autoimmun Rev 2010;9:516-20.
12. Ansari FZ, Alam S, Jain P, Akhter S, Ansari MZ. Vitiligo and its herbal treatment. Pharm Rev 2008;12:137-9.
13. Howitz J, Brodthagen H, Schwartz M, Thomsen K. Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. Arch Dermatol. 1977 Jan;113(1):47–52.
14. Krüger C,Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012 Oct;51(10):1206–12.
15. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol 2016; 74:295.
16. Joye A, Suhler E. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2021; 32:574
17. Andrade A, Pithon M. Alezzandrini syndrome: report of a sixth clinical case. Dermatology 2011; 222:8.
18. ALEZZANDRINI AA. [UNILATERAL MANIFESTATIONS OF TAPETO-RETINAL DEGENERATION,VITILIGO, POLIOSIS, GREY HAIR AND HYPOACOUSIA]. Ophthalmologica 1964; 147:409.
19. Ezzedine K, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics 2016; 138.
20. Gianfaldoni S., Wollina U., Tirant M., Tchernev G., Lotti J., Satolli F., Rovesti M., França K., Lotti T. Herbal Compounds for the Treatment of Vitiligo: A Review, Open Access Maced J Med Sci. 2018 Jan 25; 6(1):203-207.
21. Parsad D., Pandhi R., Juneja A. Effectiveness of oral Ginkgo biloba in Treating limited, slowly spreading Vitiligo. Clin Exp Dermatol. 2003; 28(3):285-7
22. Gianfaldoni S., Wollina U., Tirant M., Tchernev G., Lotti J., Satolli F., Rovesti M., França K., Lotti T. Herbal Compounds for the Treatment of Vitiligo: A Review, Open Access Maced J Med Sci. 2018 Jan 25;
23. Naini F.F., Shooshtari A.V., Ebrahimi B. The effect of Pseudocatalase/superoxide dismutase In the treatment of vitiligo: A pilot Study. J Res Pharm Pract. 2012; 1(2):77-80.
24. Yuksel E.P., Aydin F., Senturk N. Comparison of the efficacy of narrow Band ultraviolet B and narrow band Ultraviolet B plus topical catalase/superoxide dismutase treatment in Vitiligo patients.Eur J Dermatol. 2009; 19(4):341 -344.
25. Buggiani G., Tsampau D., Hercogovà J. Clinical efficacy of a novel topical formulation for vitiligo: compared Evaluation of different treatment Modalities in 149 patients. Dermatol Ther. 2012; 25(5):472-476.
26. Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B. StudiesOn vitiligo. I. Epidemiological profile in Calcutta, India. Genet Epidemiol 1985;2:71e8.
27. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of Vitiligo. Arch Dermatol 1993;129:994e8.
28. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, et al.Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2. Hum Mol Genet 2002;11:661e7.
29. Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J,et al. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 2003;72:1560e4.
30. Spritz RA, Gowan K, Bennett DC, Fain PR. Novel vitiligo susceptibility loci on chromosomes (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004;74:188e91.
31. Lotti, T.; Berti, S.; Moretti, S. Vitiligo therapy. Expert Opin. Pharmacother. 2009, 10, 2779–2785.
32. Savin, J.A. The hidden face of dermatology. Clin. Exp. Dermatol. 1993, 18, 393–395.
33. Mulekar, S.V.; Isedeh, P. Surgical interventions for vitiligo: An evidence-based review. Br. J. Dermatol. 2013, 169, 57–66.
34. Anbar, T.S.; Hegazy, R.A.; Picardo, M.; Taieb, A. Beyond vitiligo guidelines: Combined stratified/personalized approaches for the vitiligo patient. Exp. Dermatol. 2014, 23, 219–223.
35. Umama yezdani, Mahmood Ali, Mohammad Gayoor khan, Ayush Kumar, prince bhalla, mayur sadar. World journal of pharmaceutical Research. Volume 8, Issue 9. 884-892.

Ahead of Print Subscription Review Article
Volume 16
01
Received 26/09/2025
Accepted 25/11/2025
Published 30/11/2025
Publication Time 65 Days
78

Login


My IP

PlumX Metrics